<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00898781</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000582085</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>MC0744</secondary_id>
    <secondary_id>07-006779</secondary_id>
    <nct_id>NCT00898781</nct_id>
  </id_info>
  <brief_title>Study of Circulating Cancer Cells in Patients With Metastatic Breast, Ovarian, Colon, or Pancreatic Cancer</brief_title>
  <official_title>Molecular Detection of Circulating Cancer Cells in Breast, Ovarian, Colon and Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Counting the number of circulating cancer cells in samples of blood from patients&#xD;
      with metastatic cancer may help doctors find out how much the cancer has spread.&#xD;
&#xD;
      PURPOSE: This research study is looking at the number of circulating cancer cells in patients&#xD;
      with metastatic breast cancer, ovarian cancer, colon cancer, or pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To assess frequency of circulating tumor cells (CTCs) in patients with metastatic&#xD;
           ovarian, breast, pancreatic, and colon cancers.&#xD;
&#xD;
        -  To assess the variability in number of CTCs between patients with the same tumor type.&#xD;
&#xD;
        -  To correlate the number of CTCs with extent of tumor burden as measured by tumor&#xD;
           markers, imaging, and the number of metastatic sites and proliferation and apoptotic&#xD;
           markers.&#xD;
&#xD;
      OUTLINE: Blood samples are collected before treatment and analyzed using molecular detection&#xD;
      techniques to detect circulating cancer cells. Samples are assessed by immunofluorescence for&#xD;
      markers of proliferation and survival (e.g., EGFR, phosphorylated EGFR, AKT, phosphorylated&#xD;
      AKT, cytokeratins, MAPK, Src, and FAK).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to poor accrual&#xD;
  </why_stopped>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of circulating cancer cells (CTC)</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Variability in number of CTCs between patients with the same tumor type</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of the number of CTCs with extent of tumor burden as measured by tumor markers, imaging, and the number of metastatic sites and proliferation and apoptotic markers</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Metastatic Breast Cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Metastatic Ovarian Cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Metastatic Pancreatic Cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Metastatic Colon Cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 3 Ovarian Cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Locally Advanced Pancreatic Cancer</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Registration - Inclusion Criteria&#xD;
&#xD;
          -  Radiographic or marker evidence of metastatic ovarian, breast, pancreatic, or colon&#xD;
             disease or pre-operative clinically staged 3 ovarian cancer or locally advanced or&#xD;
             metastatic pancreatic cancer.&#xD;
&#xD;
          -  Not received prior therapy for metastatic disease.&#xD;
&#xD;
        Registration - Exclusion Criteria:&#xD;
&#xD;
        -History of any prior cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Radiographic or marker evidence of metastatic ovarian, breast, pancreatic, or colon&#xD;
             disease&#xD;
&#xD;
          -  Hormone receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  No history of any prior cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior therapy for metastatic disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Erlichman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>July 18, 2011</last_update_submitted>
  <last_update_submitted_qc>July 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Charles Erlichman, M.D.</name_title>
    <organization>Mayo Clinic Cancer Center</organization>
  </responsible_party>
  <keyword>male breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian germ cell tumor</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>ovarian sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

